A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Terameprocol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Erimos Pharmaceuticals
- 20 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 24 Apr 2008 Status changed from initiated to recruiting.